Stem Cells, Vol 13, 1-21, Copyright © 1995 by AlphaMed Press

REVIEWS

Chronic lymphoid leukemias: recent advances in biology and therapy

KA Foon
Lucille Parker Markey Cancer Center, Department of Internal Medicine, University of Kentucky Medical Center, Lexington 40536-0093, USA.

There exists a wide variety of lymphoid leukemias derived from B and T lymphocytes. These diseases have distinct immunologic and biologic features as well as varied responses to therapeutics. The most common lymphoid leukemia is chronic lymphocytic leukemia (CLL) which is a clonal proliferation of a subset of B cells expressing the CD5 antigen. Prolymphocytic leukemia is usually derived from B cells and shares some features with CLL but is clearly a distinct entity. Hairy-cell leukemia is a B cell malignancy that is uniquely responsive to a variety of biologic and chemotherapeutic agents. Waldenstrom's macroglobulinemia is a B cell malignancy that secretes immunoglobulin M (IgM) and may present with the hyperviscosity syndrome. Other B cell malignancies that less commonly present as leukemias include non-Hodgkin's lymphomas such as follicular lymphoma or mantle zone lymphoma. Multiple myeloma may rarely present or evolve into a plasma cell leukemia, typically in far advanced disease. T cell malignancies that may present as chronic lymphoid leukemias, and in the past have often been referred to as T cell chronic lymphocytic leukemia, are large granular lymphocytic leukemia, adult T cell leukemia/lymphoma, Sezary cell leukemia and rare cases of non-Hodgkin's lymphoma that are T cell derived and may present or evolve into a leukemic phase. There is also a rare T cell counterpart of prolymphocytic leukemia. Distinguishing these diseases is critical for optimal care of these patients.

This article has been cited by other articles:

				H. Ludwig, B. G. M. Durie, V. Bolejack, I. Turesson, R. A. Kyle, J. Blade, R. Fonseca, M. Dimopoulos, K. Shimizu, J. San Miguel, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group Blood, April 15, 2008; 111(8): 4039 - 4047. [Abstract] [Full Text] [PDF]

				J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF]

				S. J. Choi, T. Oba, N. S. Callander, D. F. Jelinek, and G. D. Roodman AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma Blood, May 15, 2003; 101(10): 3778 - 3783. [Abstract] [Full Text] [PDF]

				F. A. Mettler Jr. and G. L. Voelz Major Radiation Exposure -- What to Expect and How to Respond N. Engl. J. Med., May 16, 2002; 346(20): 1554 - 1561. [Full Text] [PDF]

				S. J. Choi, J. C. Cruz, F. Craig, H. Chung, R. D. Devlin, G. D. Roodman, and M. Alsina Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood, July 15, 2000; 96(2): 671 - 675. [Abstract] [Full Text] [PDF]

				S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy J. Clin. Oncol., March 13, 2000; 18(6): 1360 - 1377. [Abstract] [Full Text] [PDF]

				J. Nilsson, O. Soderberg, K. Nilsson, and A. Rosen Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells Blood, February 15, 2000; 95(4): 1420 - 1426. [Abstract] [Full Text] [PDF]